Loading, please wait ...


News Analytics

.
The dose 2 immunogenicity population that could be evaluated included participants who underwent randomization and received two BNT162b2 doses in accordance with the protocol, received dose 2 within the prespecified window (19 to 42 days after dose 1), had at least one valid and determinate immunogenicity result from a blood sample obtained within 28 to 42 days after dose 2, and had no major protocol deviations.

Subject Matter

  • Healthcare 54.93%
    • Hospitals, doctors and medical care 100.00%
  • Science and technology 45.07%

Emotional Reaction

Sentiment

Positive

Neutral

Negative

Definitions